A report demonstrates effective symptom relief in a 70-year-old man with sarcomatoid carcinoma using a novel treatment.
DOTA-IBA is a novel bone-targeting precursor for metastatic bone disease. It was radiolabeled with 225 Ac to generate the alpha-emitting therapeutic agent 225 Ac-DOTA-IBA. In this report, a 70-year-old man with pulmonary sarcomatoid carcinoma and extensive skeletal metastases was treated upfront with 2 cycles of 225 Ac-DOTA-IBA. The patient showed excellent symptomatic and radiological response. In addition, no adverse effects were observed in the patient.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: